Workshop Descriptions

Friday May 7, 2021

4:10 - 4:50 PM
POCUS in HF: Back by Popular Demand
This practical workshop will build on last year’s popular session on Point of care Ultrasound (POCUS) for cardiologists. POCUS has emerged as a useful tool for rapid identification of acutely decompensated HF that can help guide clinical decision-making and timely interventions. This year’s workshop will offer participants some useful “do’s and don’ts” for successful integration of POCUS into clinical practice.
Ryan Davey, MD
Sharon Mulvagh, MD
4:10 - 4:50 PM
Guide to Drug Withdrawal in HFrecEF
Initiation and titration of medical therapies for heart failure is part of a cardiologist’s day to day practice; however, less attention is normally afforded to withdrawal of medications when they are no longer consistent with goals of care. This workshop will explore when, how and in whom HF therapies can be safely withdrawn, and how to monitor patients during and after de-titration.
Abhinav Sharma, MD
4:10 - 4:50 PM
Identifying Frailty in HF and Why it Matters
Frailty is common in older patients with heart failure, but it is not synonymous with age alone. This workshop will help participants recognize who to screen for frailty, how to assess the degree of frailty, and how to adapt HF treatment goals and management plans in patients who are frail.
Jonathan Afilalo, MD
4:10 - 4:50 PM
Optimizing HF and Device Therapy After Cardiac Device Implantation
Implantable devices are an increasingly important tool for the long-term management of heart failure patients. This workshop will discuss the optimization of aspects of post-implantation care, from medical management and device management to patient monitoring and assessment, with the ultimate goals of maximizing patient outcomes.
Kiran Sidhu, MD

Saturday May 8, 2021

11:40 AM - 12:20 PM
A Shared Decision-Making Approach to Goals of Care
Contemporary heart failure guidelines advocate for shared care plans with clearly defined patient-centered goals of care across all phases of the patient journey. During this workshop, participants will explore strategies to individualize palliative goals of care that reflect patient values as they evolve along their HF journey.
Caroline McGuinty, MD
11:40 AM - 12:20 PM
Practical Approach to Heart Failure Medication
Advances in the medical management of heart failure have contributed to improved patient outcomes, but they are also increasing the complexity of care. One such example is the evolution of optimal medical management of HFrEF from triple therapy to “quadruple therapy.” This workshop for nurses will address practical issues related to the initiation, follow-up, monitoring, and optimization of quadruple medical therapy for HF including essential points for patient and family education that can help support adherence and safety.
Rodolfo Pike, NP
Nadia Thomson, NP
11:40 AM - 12:20 PM
Virtual HF Monitoring
The global pandemic has ushered in an era of virtual care that includes remote monitoring and management of heart failure patients. This workshop will explore the rapidly evolving landscape of virtual HF care and discuss how new tools and technologies can be leveraged to create new models of care for appropriate patients and integrate into existing models of care.
Patrice Lindsay, RN, PhD
Mary O'Sullivan, RN
11:40 AM - 12:20 PM
L’échocardiographie chez l’insuffisant cardiaque: Paramètres au-delà de la FEVG
L’atelier révise l’utilité de l’échocardiographie dans la prise en charge et l’évaluation pronostique du patient insuffisant cardiaque. Cet atelier présente également une courte discussion sur l’évaluation de la fonction ventriculaire à l’aide des nouvelles avancées en échocardiographie.
Catherine Bourque, MD
3:30 - 4:10 PM
Effects of Non-CV Drugs on the Heart
Multimorbidity is the rule rather than the exception in heart failure. Thus, it is critical for clinicians to appreciate the wide array of non-cardiovascular drugs that are commonly taken by HF patients and how these may impact on guideline-directed medical HF therapies. This workshop will address some of the common and evolving drug-drug and drug-disease interactions that clinicians should be alert for, and how to minimize risk to patients.
Ricky Turgeon, PharmD
3:30 - 4:10 PM
How to Involve QA in Hospital HF Care
Despite recent advancements that have demonstrated improved outcomes in heart failure, many patients still fail to meet benchmark standards of care. This workshop is focused on practical strategies that can be adapted to locoregional care settings to optimize the management of HF patients to meet guideline-recommended standards.
Robert McKelvie, MD
3:30 - 4:10 PM
CCS/CHFS Heart Failure Guidelines - Evidence to Support Innovation in Practice
The 2021 CCS/CHFS Heart Failure Guidelines define a new standard of care for the pharmacologic management of patients with heart failure and reduced ejection fraction (HFrEF). Since the 2017 Comprehensive Update of the CCS Guidelines for the Management of Heart Failure, substantial new evidence has emerged to inform the best course of therapy for patients. This presentation provides evidence-based recommendations with respect to the role and clinical setting in which novel pharmacologic therapies should be prescribed, in conjunction with other conventional and long-established HFrEF therapies. Practical strategies to apply the new guidelines into daily clinical practice will also be discussed.
Sean Virani, MD
3:30 - 4:10 PM
Lignes directrices de la SCC et de la SCIC sur l’insuffisance cardiaque - Preuves soutenant l’innovation dans la pratique
Les Lignes directrices de la SCC et de la SCIC sur l’insuffisance cardiaque définissent une nouvelle norme de soins pour la prise en charge des patients atteints d’insuffisance cardiaque avec fraction d’éjection réduite (ICFER). Depuis la mise à jour complète 2017 des Lignes directrices de la SCC pour la prise en charge de l’insuffisance cardiaque, de nouvelles preuves substantielles sont apparues afin de documenter la meilleure façon de traiter les patients. Cette présentation propose des recommandations fondées sur des preuves à l’égard du rôle et du milieu clinique où les nouvelles pharmacothérapies devraient être prescrites, conjointement à d’autres thérapies d’ICFER conventionnelles et reconnues depuis longtemps. On y discutera aussi de stratégies pratiques pour la mise en œuvre des nouvelles lignes directrices dans la pratique clinique quotidienne.
Eileen O’Meara, MD
3:30 - 4:10 PM
What Has ISCHEMIA Taught us About Coronary Revascularization for HFrEF
Ischemic heart disease is one of the most common etiologies of heart failure that can be successfully managed with coronary revascularization. Observational studies suggested that burden of myocardial ischemia could effectively target revascularization procedures in patients with ischemic cardiomyopathy. However, the ISCHEMIA trial has called these findings into question. This workshop will critically examine the benefits and limitations of nuclear cardiology for the identification of ischemia and selection of revascularization in patients with HF.
Robert Miller, MD


Follow @CanHFSociety Along on Twitter